News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Sarah Rutherford, MD, Weill Cornell Medical College

Articles by Sarah Rutherford, MD, Weill Cornell Medical College

ASH 2020 Updates in Relapsed/Refractory B-Cell Lymphomas

ByJennifer Woyach, MD, Ohio State University,Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute,Nathan H. Fowler, MD, MD Anderson Cancer Center,Sarah Rutherford, MD, Weill Cornell Medical College

January 22nd 2021

ASH 2020 Updates in Non-CLL B-Cell Lymphomas

ByJennifer Woyach, MD, Ohio State University,Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute,Nathan H. Fowler, MD, MD Anderson Cancer Center,Sarah Rutherford, MD, Weill Cornell Medical College

January 22nd 2021

ASH 2020 Updates in CLL

ByJennifer Woyach, MD, Ohio State University,Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute,Nathan H. Fowler, MD, MD Anderson Cancer Center,Sarah Rutherford, MD, Weill Cornell Medical College

January 22nd 2021

Latest Updated Articles

$ASH 2020 Updates in Relapsed/Refractory B-Cell Lymphomas$
ASH 2020 Updates in Relapsed/Refractory B-Cell Lymphomas
January 22nd 2021
ASH 2020 Updates in CLL
January 22nd 2021
ASH 2020 Updates in Non-CLL B-Cell Lymphomas
January 22nd 2021

Trending on OncLive

Bexobrutideg Could Pave the Way for BTK Degraders in R/R Chronic Lymphocytic Leukemia

Domvanalimab/Zimberelimab Plus Chemotherapy Fails to Improve OS in HER2-Negative Gastroesophageal Adenocarcinoma

Extended FOLFOX, Atezolizumab Duration Linked With Improved DFS in Stage III dMMR Colon Cancer

ESR1 Mutations Steer the Oral SERD Story in Breast Cancer: With Sara Nunnery, MD, MSCI; and MinhTri Nguyen, MD

Dr Shah on the Significance of DAYBreak CLL-201 and Bexobrutideg for the CLL Treatment Paradigm